ATHA RSI Chart
Last 7 days
22.1%
Last 30 days
28.4%
Last 90 days
-24.3%
Trailing 12 Months
-1.8%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2023 | 0 | 0 | 0 | 0 |
2022 | 9.2M | 7.9M | 6.5M | 5.2M |
2021 | 3.2M | 5.1M | 7.0M | 8.8M |
2020 | 1.0M | 0 | 0 | 1.3M |
2019 | 0 | 0 | 0 | 754.0K |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Jan 05, 2024 | worthington mark | sold | -7,018 | 2.91 | -2,412 | general counsel |
Jan 05, 2024 | litton mark james | sold | -14,026 | 2.91 | -4,820 | chief executive officer |
Jan 05, 2024 | lenington rachel | sold | -7,018 | 2.91 | -2,412 | coo and cdo |
Jan 05, 2024 | litton mark james | sold | -14,026 | 2.91 | -4,820 | ceo |
Jan 05, 2024 | lenington rachel | sold | -7,018 | 2.91 | -2,412 | chief operating officer |
Jan 05, 2024 | church kevin | sold | -7,018 | 2.91 | -2,412 | chief scientific officer |
Jan 05, 2024 | worthington mark | sold | -7,018 | 2.91 | -2,412 | general counsel |
Jan 05, 2024 | gengos andrew | sold | -3,515 | 2.91 | -1,208 | cfo and chief business officer |
Jan 04, 2024 | lenington rachel | acquired | - | - | 10,000 | coo and cdo |
Jan 04, 2024 | worthington mark | acquired | - | - | 10,000 | general counsel |
Which funds bought or sold ATHA recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
May 15, 2024 | TWO SIGMA ADVISERS, LP | added | 23.74 | 286,832 | 1,012,430 | -% |
May 15, 2024 | GOLDMAN SACHS GROUP INC | new | - | 109,740 | 109,740 | -% |
May 15, 2024 | Royal Bank of Canada | reduced | -77.33 | -64,000 | 22,000 | -% |
May 15, 2024 | PUBLIC EMPLOYEES RETIREMENT SYSTEM OF OHIO | new | - | 22,742 | 22,742 | -% |
May 15, 2024 | BRIDGEWAY CAPITAL MANAGEMENT, LLC | reduced | -17.02 | -33,171 | 482,166 | 0.01% |
May 15, 2024 | TWO SIGMA INVESTMENTS, LP | added | 39.97 | 427,265 | 1,166,160 | -% |
May 15, 2024 | PERCEPTIVE ADVISORS LLC | unchanged | - | 1,674,920 | 14,804,100 | 0.26% |
May 15, 2024 | TANG CAPITAL MANAGEMENT LLC | reduced | -26.03 | -464,658 | 2,336,440 | 0.24% |
May 15, 2024 | ALGERT GLOBAL LLC | new | - | 40,000 | 40,000 | -% |
May 15, 2024 | BAKER BROS. ADVISORS LP | unchanged | - | 977,680 | 8,641,430 | 0.11% |
Unveiling Athira Pharma Inc's Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to Athira Pharma Inc)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
MRNA | 50.9B | 6.8B | -8.52 | 7.43 | ||||
HILS | 22.5B | 216.3K | -2.5K | 104.0K | ||||
ALNY | 19.1B | 2.0B | -57.61 | 9.55 | ||||
BMRN | 14.6B | 2.5B | 71.11 | 5.91 | ||||
INCY | 12.8B | 3.8B | 17.13 | 3.39 | ||||
MID-CAP | ||||||||
BBIO | 5.8B | 107.9M | -10.63 | 48.09 | ||||
APLS | 5.1B | 524.1M | -12.22 | 9.73 | ||||
AXSM | 3.7B | 251.0M | -12.4 | 14.64 | ||||
ARWR | 3.1B | 240.7M | -6.6 | 12.77 | ||||
ACAD | 2.5B | 813.8M | -1.4K | 3.01 | ||||
SMALL-CAP | ||||||||
NVAX | 2.0B | 996.6M | -5.07 | 2.03 | ||||
CPRX | 1.9B | 411.3M | 29.69 | 4.7 | ||||
CRBP | 489.5M | 881.7K | -14.5 | 481.06 | ||||
INO | 330.9M | 4.9M | -2.65 | 67.99 | ||||
IBIO | 15.7M | 2.1M | -0.68 | 7.61 |
Athira Pharma Inc News
Income Statement (Quarterly) | ||||||||||||||
Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q1 | 2019Q4 |
Revenue | - | - | - | 1,227,000 | 2,959,000 | 2,596,500 | 2,234,000 | 2,336,000 | 2,079,000 | 2,589,000 | 1,831,000 | - | - | - |
Costs and Expenses | 6.3% | 31,640,000 | 29,770,000 | 32,927,000 | 24,133,000 | 23,569,000 | 23,387,000 | 18,778,000 | 17,826,000 | 16,637,000 | 10,781,000 | 9,079,000 | 1,267,000 | - |
S&GA Expenses | 18.3% | 10,025,000 | 8,477,000 | 7,691,000 | 7,168,000 | 8,766,000 | 8,927,000 | 6,160,000 | 7,119,000 | 4,613,000 | 3,336,000 | 3,892,000 | 675,000 | - |
R&D Expenses | 1.5% | 21,615,000 | 21,293,000 | 15,236,000 | 16,965,000 | 14,803,000 | 14,460,000 | 12,618,000 | 10,707,000 | 12,024,000 | 7,445,000 | 5,187,000 | 592,000 | - |
Net Income | -6.4% | -29,597,000 | -27,820,000 | -30,135,000 | -20,189,000 | -24,335,000 | -20,980,000 | -16,339,000 | -15,674,000 | -13,974,000 | -8,866,000 | -7,702,000 | -1,805,000 | - |
Net Income Margin | -5.1% | -20.88 | -19.86 | -18.53 | -12.55 | -9.81 | -7.25 | -6.21 | -6.64 | -7.68 | -8.44 | - | - | - |
Free Cashflow | 8.0% | -24,315,000 | -26,435,000 | -15,668,000 | -21,884,000 | -18,741,000 | -17,317,000 | -19,204,000 | -10,427,000 | -7,431,000 | -7,609,000 | - | - | - |
Balance Sheet | ||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2018Q4 |
Assets | -16.7% | 133 | 160 | 185 | 208 | 233 | 258 | 274 | 292 | 313 | 332 | 347 | 360 | 369 | 280 | 268 | - | - | - | - |
Current Assets | -16.9% | 129 | 155 | 179 | 192 | 193 | 208 | 229 | 256 | 269 | 261 | 239 | 290 | 312 | 192 | 232 | - | - | 2.00 | 5.00 |
Cash Equivalents | -14.1% | 78.00 | 91.00 | 110 | 114 | 105 | 96.00 | 87.00 | 95.00 | 118 | 111 | 107 | 132 | 128 | 61.00 | 166 | - | - | 2.00 | 3.00 |
Net PPE | -7.2% | 3.00 | 3.00 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 | 3.00 | 3.00 | 3.00 | 3.00 | 1.00 | - | - | - | - |
Liabilities | -11.1% | 27.00 | 30.00 | 30.00 | 23.00 | 22.00 | 23.00 | 12.00 | 11.00 | 11.00 | 11.00 | 11.00 | 9.00 | 6.00 | 5.00 | 8.00 | 7.00 | 6.00 | 5.00 | 3.00 |
Current Liabilities | -11.2% | 26.00 | 29.00 | 29.00 | 22.00 | 20.00 | 21.00 | 10.00 | 10.00 | 9.00 | 9.00 | 9.00 | 8.00 | 4.00 | 4.00 | 8.00 | - | - | 1.00 | 1.00 |
Shareholder's Equity | -18.0% | 107 | 130 | 155 | 185 | 211 | 235 | 262 | 281 | 302 | 321 | 336 | 351 | 363 | 274 | 259 | - | - | - | - |
Retained Earnings | -8.5% | -335 | -309 | -281 | -248 | -219 | -191 | -161 | -141 | -116 | -95.89 | -79.56 | -63.88 | -49.91 | -41.04 | -33.34 | - | - | -21.09 | -15.93 |
Additional Paid-In Capital | 0.6% | 442 | 440 | 437 | 435 | 432 | 429 | 426 | 424 | 420 | 417 | 416 | 415 | 413 | 315 | 293 | - | - | 1.00 | 1.00 |
Shares Outstanding | 0.4% | 38.00 | 38.00 | 38.00 | 38.00 | 38.00 | 38.00 | 38.00 | 38.00 | 38.00 | 37.00 | 37.00 | 36.00 | 36.00 | - | - | - | - | - | - |
Float | - | - | - | - | 96.00 | - | - | - | 99.00 | - | - | - | 328 | - | - | 461 | - | - | - | - |
Cashflow (Quarterly) | |||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2018Q4 |
Cashflow From Operations | 1.9% | -25,804 | -26,293 | -23,984 | -24,282 | -26,194 | -15,667 | -21,640 | -18,590 | -16,572 | -18,177 | -10,299 | -7,317 | -7,305 | -10,665 | -9,411 | -2,862 | -1,175 | - | - | - |
Share Based Compensation | 20.2% | 2,679 | 2,228 | 2,494 | 3,119 | 2,782 | 2,360 | 2,420 | 3,095 | 2,731 | 1,435 | 1,105 | 1,109 | 974 | 415 | 111 | 49.00 | 58.00 | - | - | - |
Cashflow From Investing | 104.1% | 13,041 | 6,391 | 20,690 | 32,486 | 35,522 | 24,647 | 13,632 | -4,461 | 23,846 | 21,373 | -14,199 | 11,455 | -22,708 | -115,758 | -94,313 | 2.00 | 1.00 | - | - | - |
Cashflow From Financing | -100.0% | - | 152 | - | 242 | 99.00 | 147 | - | 297 | 210 | 13.00 | 125 | -260 | 97,211 | 21,323 | 184,283 | 85,304 | 1,840 | - | - | - |
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands | 3 Months Ended | |
---|---|---|
Mar. 31, 2024 | Mar. 31, 2023 | |
Operating expenses: | ||
Research and development | $ 21,236 | $ 21,293 |
General and administrative | 6,451 | 8,477 |
Total operating expenses | 27,687 | 29,770 |
Loss from operations | (27,687) | (29,770) |
Grant income | 157 | |
Other income, net | 1,350 | 1,793 |
Net loss | (26,337) | (27,820) |
Unrealized gain on available-for-sale securities | 212 | 927 |
Comprehensive loss attributable to common stockholders | $ (26,125) | $ (26,893) |
Net loss per share attributable to common stockholders, basic | $ (0.69) | $ (0.73) |
Net loss per share attributable to common stockholders, diluted | $ (0.69) | $ (0.73) |
Weighted-average shares used in computing net loss per share attributable to common stockholders, basic | 38,321,573 | 37,923,402 |
Weighted-average shares used in computing net loss per share attributable to common stockholders, diluted | 38,321,573 | 37,923,402 |
Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands | Mar. 31, 2024 | Dec. 31, 2023 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 77,821 | $ 90,584 |
Short-term investments | 44,267 | 56,835 |
Prepaid expenses and other current assets | 4,920 | 5,682 |
Insurance recovery receivable related to legal settlement (Note 7) | 1,628 | 1,628 |
Total current assets | 128,636 | 154,729 |
Restricted cash | 631 | 631 |
Property and equipment, net | 3,144 | 3,388 |
Operating lease right-of-use asset | 992 | 1,049 |
Other long-term assets | 55 | 448 |
Total assets | 133,458 | 160,245 |
Current liabilities: | ||
Accounts payable | 681 | 129 |
Accrued liabilities | 14,537 | 18,343 |
Accrued legal settlement | 10,000 | 10,000 |
Current operating lease liability | 380 | 368 |
Total current liabilities | 25,598 | 28,840 |
Operating lease liability, less current portion | 1,118 | 1,217 |
Total liabilities | 26,716 | 30,057 |
Stockholders' equity: | ||
Common stock, $0.0001 par value; 900,000,000 shares authorized at March 31, 2024 and December 31, 2023, respectively; 38,326,652 and 38,172,603 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively | 4 | 4 |
Additional paid-in capital | 442,418 | 439,739 |
Accumulated other comprehensive loss | (137) | (349) |
Accumulated deficit | (335,543) | (309,206) |
Total stockholders' equity | 106,742 | 130,188 |
Total liabilities and stockholders' equity | $ 133,458 | $ 160,245 |